EP1551402A4 - Compositions pharmaceutiques n'induisant pas l'abus - Google Patents

Compositions pharmaceutiques n'induisant pas l'abus

Info

Publication number
EP1551402A4
EP1551402A4 EP03770388A EP03770388A EP1551402A4 EP 1551402 A4 EP1551402 A4 EP 1551402A4 EP 03770388 A EP03770388 A EP 03770388A EP 03770388 A EP03770388 A EP 03770388A EP 1551402 A4 EP1551402 A4 EP 1551402A4
Authority
EP
European Patent Office
Prior art keywords
abuse
pharmaceutical compositions
resistant pharmaceutical
resistant
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03770388A
Other languages
German (de)
English (en)
Other versions
EP1551402A2 (fr
Inventor
Farid Vaghefi
Gary G Liversidge
Stephen B Ruddy
Eugene R Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Verion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd, Verion Inc filed Critical Elan Pharma International Ltd
Publication of EP1551402A2 publication Critical patent/EP1551402A2/fr
Publication of EP1551402A4 publication Critical patent/EP1551402A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP03770388A 2002-09-23 2003-09-23 Compositions pharmaceutiques n'induisant pas l'abus Withdrawn EP1551402A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41286102P 2002-09-23 2002-09-23
US412861P 2002-09-23
US41349502P 2002-09-25 2002-09-25
US413495P 2002-09-25
PCT/US2003/029890 WO2004026262A2 (fr) 2002-09-23 2003-09-23 Compositions pharmaceutiques n'induisant pas l'abus

Publications (2)

Publication Number Publication Date
EP1551402A2 EP1551402A2 (fr) 2005-07-13
EP1551402A4 true EP1551402A4 (fr) 2009-05-27

Family

ID=32033627

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03770388A Withdrawn EP1551402A4 (fr) 2002-09-23 2003-09-23 Compositions pharmaceutiques n'induisant pas l'abus

Country Status (5)

Country Link
US (2) US8623412B2 (fr)
EP (1) EP1551402A4 (fr)
JP (3) JP5189242B2 (fr)
CA (1) CA2499994C (fr)
WO (1) WO2004026262A2 (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001080831A2 (fr) * 2000-04-27 2001-11-01 Verion Inc. Microcapsules a liberation d'ordre nul et commande par la temperature, et procede pour leur elaboration
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1492505B1 (fr) 2002-04-05 2015-06-03 Euro-Celtique S.A. Preparation pharmaceutique contenant oxycodone et naloxone
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
CA2916869A1 (fr) * 2004-06-12 2005-12-29 Jane C. Hirsh Formulations de prevention des abus
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
ES2531735T3 (es) * 2004-10-15 2015-03-18 Supernus Pharmaceuticals, Inc. Preparaciones farmacéuticas con menor potencial de abuso
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
WO2006133733A1 (fr) 2005-06-13 2006-12-21 Flamel Technologies Forme posologique orale comportant un systeme anti-abus
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
AU2008286914B2 (en) * 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
WO2009035474A1 (fr) * 2007-09-13 2009-03-19 Cima Labs Inc. Formulation médicamenteuse contre l'abus
EP2219622A1 (fr) 2007-12-06 2010-08-25 Durect Corporation Procédés utiles dans le traitement de la douleur, d'états rhumatismaux ou d'inflammations associées à un état chronique
AU2008335360A1 (en) * 2007-12-06 2009-06-18 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2713128C (fr) 2008-01-25 2016-04-05 Gruenenthal Gmbh Forme posologique pharmaceutique
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US20090194533A1 (en) * 2008-02-04 2009-08-06 Lizerbram Eric K Closure with additive reservoir
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
EP2352568B1 (fr) * 2008-10-02 2017-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Administration d'un polymère adsorbant pour le traitement d'une inflammation systémique
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010066034A1 (fr) * 2008-12-12 2010-06-17 Paladin Labs Inc. Préparation de méthadone
ES2509497T3 (es) 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2798702A1 (fr) 2010-05-11 2011-11-17 Cima Labs Inc. Formes dosifiees orales a liberation prolongee contenant du metoprolol resistantes aux alcools
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (fr) 2012-04-18 2018-08-22 Grünenthal GmbH Forme pharmaceutique inviolable et résistante au basculement de dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014106865A1 (fr) * 2013-01-07 2014-07-10 Alkem Laboratories Ltd. Composition pharmaceutique à libération prolongée, permettant d'éviter les abus, comprenant du tapentadol ou un sel pharmaceutiquement acceptable de celui-ci et ses procédés de préparation
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3003279A1 (fr) 2013-05-29 2016-04-13 Grünenthal GmbH Forme pharmaceutique inviolable contenant une ou plusieurs particules
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3073994A1 (fr) 2013-11-26 2016-10-05 Grünenthal GmbH Préparation de composition pharmaceutique en poudre par cryo-broyage
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015173195A1 (fr) 2014-05-12 2015-11-19 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US10004699B2 (en) * 2014-06-09 2018-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016170097A1 (fr) 2015-04-24 2016-10-27 Grünenthal GmbH Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant.
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
WO2018119033A1 (fr) * 2016-12-20 2018-06-28 Cima Labs Inc. Formes posologiques résistantes aux abus et dissuadant les abus
US10149843B1 (en) 2017-02-07 2018-12-11 Gneus Lifescineces Inc. Pharmaceutical compositions and methods of using the same
US10231961B1 (en) 2017-02-07 2019-03-19 Genus Lifesciences Inc. Pharmaceutical compositions and methods of using the same
US10413505B1 (en) 2017-02-07 2019-09-17 Genus Lifesciences Inc. Pharmaceutical compositions and methods of using the same
US12582606B2 (en) 2019-04-15 2026-03-24 Sunsho Pharmaceutical Co., Ltd. Tablet and method for producing tablet
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0514008A1 (fr) * 1991-04-19 1992-11-19 Takeda Chemical Industries, Ltd. Préparations pharmaceutiques à base de matrices au d'enrobages adhérents à la muqueux gastrointestinale
US5209879A (en) * 1990-04-06 1993-05-11 Redding Bruce K Method for inducing transformations in waxes
WO1996014058A1 (fr) * 1994-11-04 1996-05-17 Euro-Celtique, S.A. Formulations opioides administrables par voie orale et obtenues par fusion-extrusion
WO2001032148A1 (fr) * 1999-10-29 2001-05-10 Euro-Celtique, S.A. Formulations d'hydrocodone a liberation lente
WO2001058451A1 (fr) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Formes orales inviolables d'agonistes de l'opioide
US20010044026A1 (en) * 2000-04-27 2001-11-22 Farid Vaghefi Zero order release and temperature-controlled microcapsules and process for the preparation thereof
WO2003039514A1 (fr) * 2001-10-18 2003-05-15 Verion Inc. Microspheres a matrice a microcapsules, compositions pharmaceutiques ameliorant l'absorption et methodes associees

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1174695A (en) * 1914-07-22 1916-03-07 Moses E Bloom Means for preventing the accidental taking of poison-tablets.
US1204793A (en) * 1916-02-16 1916-11-14 Louis Spencer Levy Tablet.
US1204794A (en) * 1916-07-19 1916-11-14 Louis Spencer Levy Poison-deterrent.
US1349326A (en) * 1920-01-20 1920-08-10 Charles T Davis Poison-tablet
US1893008A (en) * 1930-05-31 1933-01-03 Firm Lonza Elek Zitaetswerke U Method and means for prevention of metaldehyde poisonings
US2258414A (en) * 1940-07-20 1941-10-07 Du Pont Denaturant
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3260646A (en) * 1962-10-19 1966-07-12 Ferring Ab Medication with mechanism to prevent overdosage
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4175119A (en) * 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4493848A (en) * 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4532139A (en) * 1983-07-14 1985-07-30 The Procter & Gamble Company Compounds and compositions useful for producing analgesia
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
FR2598321B1 (fr) * 1986-05-12 1988-09-09 Fontaine Michel Procede de preparation d'extraits vegetaux de piment (genre capsicum) et de peuplier (genre populus) et produits ainsi obtenus, utilisables separement ou en melange dans le traitement et la prevention de la toxicomanie alcoolique
US5008293A (en) * 1988-07-22 1991-04-16 Berger Frank M Process for the treatment of the skin to alleviate skin diseases arising from contact sensitization or irritation utilizing p-substituted phenoxy alkanols
US4997853A (en) * 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
US5035882A (en) * 1990-04-12 1991-07-30 Warner-Lambert Company Combination of formate esters and pepper-like constituents as an orally-consumable chloroform substitute
US4980169A (en) * 1990-05-03 1990-12-25 Warner-Lambert Company Flavor enhancing and increasing efficacy of cough drops
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5178879A (en) * 1992-04-17 1993-01-12 Michael Adekunle Capsaicin gel
US5985860A (en) * 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL109944A (en) * 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
EP0672416A1 (fr) * 1994-03-14 1995-09-20 Euro-Celtique S.A. Composition pharmaceutique à base de diamorphine
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US6455076B1 (en) * 1994-12-21 2002-09-24 Gary S. Hahn Formulations and methods for reducing skin irritation
US5756107A (en) * 1994-12-21 1998-05-26 Cosmederm Technologies Formulations and methods for reducing skin irritation
US6197830B1 (en) * 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US6239180B1 (en) * 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
US6248788B1 (en) * 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US5958436A (en) * 1995-12-21 1999-09-28 Cosmederm Technologies Formulations and methods for reducing skin irritation
DE69732868T2 (de) * 1996-11-25 2006-04-13 Toray Industries, Inc. Mittel gegen Juckreiz
ATE481970T1 (de) * 1997-03-13 2010-10-15 James N Campbell Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
WO1998053825A1 (fr) * 1997-05-27 1998-12-03 Algos Pharmaceutical Corporation Composition de medicament analgesique contenant un capsaicinoide et un agent de potentialisation de celui-ci
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
CA2314896C (fr) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. Procede prevenant l'abus des doses orales d'opioides
JP2001526228A (ja) * 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
US6277389B1 (en) * 1999-03-31 2001-08-21 Erroll M. Pullen Non-toxic aqueous pesticide
US6284797B1 (en) * 1999-04-12 2001-09-04 Donald A. Rhodes Topical treatment of pain and to promote healing
CA2379987A1 (fr) * 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Preparation d'opioide a liberation continue
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
ES2226886T3 (es) * 1999-08-31 2005-04-01 Grunenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
SE517174C2 (sv) * 1999-09-15 2002-04-23 Johnny Waerneloev Sätt och anordning för identifikation och styrning av hantering av nycklar och dylikt
US6197823B1 (en) * 1999-09-29 2001-03-06 Medical Merchandising, Inc. Pain reliever and method of use
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6349724B1 (en) * 2000-07-05 2002-02-26 Compumedics Sleep Pty. Ltd. Dual-pressure blower for positive air pressure device
CA2317987A1 (fr) * 2000-09-11 2002-03-11 Jean G. Robillard Plate-forme auto-elevatrice amelioree
CN1525851A (zh) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
JP2005515960A (ja) * 2001-05-11 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 乱用耐性のオピオイド投薬形態
US20030064122A1 (en) * 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
WO2003002100A1 (fr) * 2001-06-26 2003-01-09 Farrell John J Systeme d'administration de narcotique inviolable
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5209879A (en) * 1990-04-06 1993-05-11 Redding Bruce K Method for inducing transformations in waxes
EP0514008A1 (fr) * 1991-04-19 1992-11-19 Takeda Chemical Industries, Ltd. Préparations pharmaceutiques à base de matrices au d'enrobages adhérents à la muqueux gastrointestinale
WO1996014058A1 (fr) * 1994-11-04 1996-05-17 Euro-Celtique, S.A. Formulations opioides administrables par voie orale et obtenues par fusion-extrusion
WO2001032148A1 (fr) * 1999-10-29 2001-05-10 Euro-Celtique, S.A. Formulations d'hydrocodone a liberation lente
WO2001058451A1 (fr) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Formes orales inviolables d'agonistes de l'opioide
US20010044026A1 (en) * 2000-04-27 2001-11-22 Farid Vaghefi Zero order release and temperature-controlled microcapsules and process for the preparation thereof
WO2003039514A1 (fr) * 2001-10-18 2003-05-15 Verion Inc. Microspheres a matrice a microcapsules, compositions pharmaceutiques ameliorant l'absorption et methodes associees

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Drugs: Fact and Fiction/Stimulants", Retrieved from the Internet <URL:https://en.wikibooks.org/wiki/Drugs:Fact_and_Fiction/Stimulants> *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1991, PURDUE B N ET AL: "Two deaths from intravenous nifedipine abuse.", Database accession no. NLM1782148 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 1998 (1998-11-01), HUNT T E ET AL: "The effects of serotonin biosynthesis inhibition on nicotine and nifedipine-induced analgesia in rats.", Database accession no. NLM9806690 *
HUNT T E ET AL: "The effects of serotonin biosynthesis inhibition on nicotine and nifedipine-induced analgesia in rats.", ANESTHESIA AND ANALGESIA NOV 1998, vol. 87, no. 5, November 1998 (1998-11-01), pages 1109 - 1112, ISSN: 0003-2999 *
PURDUE B N ET AL: "Two deaths from intravenous nifedipine abuse.", INTERNATIONAL JOURNAL OF LEGAL MEDICINE 1991, vol. 104, no. 5, 1991, pages 289 - 291, ISSN: 0937-9827 *
ROPER T A ET AL: "Fatal diltiazem overdose: report of four cases and review of the literature", POSTGRAD MED J, vol. 69, no. 812, June 1993 (1993-06-01), pages 474 - 476 *

Also Published As

Publication number Publication date
JP2012021024A (ja) 2012-02-02
WO2004026262A3 (fr) 2004-06-10
JP2006502192A (ja) 2006-01-19
JP5189242B2 (ja) 2013-04-24
JP2015083616A (ja) 2015-04-30
WO2004026262A2 (fr) 2004-04-01
EP1551402A2 (fr) 2005-07-13
CA2499994C (fr) 2012-07-10
JP5746951B2 (ja) 2015-07-08
US20060104909A1 (en) 2006-05-18
US8623412B2 (en) 2014-01-07
US20140112980A1 (en) 2014-04-24
CA2499994A1 (fr) 2004-04-01

Similar Documents

Publication Publication Date Title
EP1551402A4 (fr) Compositions pharmaceutiques n&#39;induisant pas l&#39;abus
GB2389530B (en) Pharmaceutical compositions
GB0320382D0 (en) Pharmaceutical compositions
GB0327723D0 (en) Pharmaceutical compositions
AU2003291103A8 (en) Pharmaceutical composition
IL164547A0 (en) Pharmaceutical composition
GB2391473B (en) Pharmaceutical compositions
GB0300427D0 (en) Pharmaceutical composition
IL165878A0 (en) Pharmaceutical composition
GB0300531D0 (en) Pharmaceutical compositions
EP1648411A4 (fr) Compositions pharmaceutiques
EP1699458A4 (fr) Composition pharmaceutique
HU0302441D0 (en) Pharmaceutical compositions having antibiothic effect
ZA200605080B (en) Pharmaceutical compositions
GB0213481D0 (en) Pharmaceutical compositions
GB0300885D0 (en) Pharmaceutical composition
EP1480649A4 (fr) Compositions pharmaceutiques stables
GB0306933D0 (en) Pharmaceutical composition
GB0305579D0 (en) Pharmaceutical compositions
PL370907A1 (en) Pharmaceutical compositions
GB0307862D0 (en) Pharmaceutical composition
GB0217703D0 (en) Pharmaceutical composition
GB0225880D0 (en) Pharmaceutical compositions
GB0221068D0 (en) Pharmaceutical compositions
GB0210663D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050421

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELAN PHARMA INTERNATIONAL LIMITED

Owner name: VERION, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20090427

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/485 20060101ALI20090421BHEP

Ipc: A61K 47/14 20060101ALI20090421BHEP

Ipc: A61K 9/16 20060101AFI20090421BHEP

Ipc: A61K 47/44 20060101ALI20090421BHEP

17Q First examination report despatched

Effective date: 20090925

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELAN PHARMA INTERNATIONAL LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160422